The phase III IMspire150 trial showed that treating BRAF V600‐mutant melanoma with atezolizumab, vemurafenib, and cobimetinib significantly increased PFS from 10.6 months with vemurafenib and cobimetinib to 15.1 months (HR, 0.78; 95%CI: 0.63, 0.97; p = 0.025) without obviously adding adverse events.308. This evidence concerns the gene BRAF and melanoma.